[ET Net News Agency, 4 August 2020] Sino Biopharmaceutical Limited (01177) said the
drug for the treatment of hepatitis B "Adefovir Dipivoxil Capsules" (brand name:
Mingzheng) of the group has obtained the notice of approval of supplemental applications
issued by the National Medical Products Administration of the People's Republic of China,
which is the first product of its kind to pass the Consistency of Quality and Efficacy
Evaluation for Generic Drugs (Consistency Evaluation).
The indication of Mingzheng is for the treatment of adult chronic hepatitis B patients
with evidence of active viral replication of hepatitis B and either of persistent
elevations in serum aminotransaminases or histologically active disease with compensated
liver function. (RC)